DOAC Pharmacokinetics in Malabsorptive States

Area of Science:

• Pharmacology
• Gastroenterology
• Internal Medicine

Background:

• Direct oral anticoagulants (DOACs) are increasingly used for stroke prevention and venous thromboembolism treatment.
• Their efficacy depends on adequate gastrointestinal absorption, which can be compromised in malabsorptive conditions.

Purpose of the Study:

• To review the effectiveness of DOACs in patients with gastrointestinal malabsorption.
• To provide guidance on anticoagulant selection in specific malabsorptive scenarios.

Main Methods:

• Literature review of studies investigating DOAC pharmacokinetics and efficacy in malabsorptive states.
• Analysis of current guidelines regarding anticoagulant use post-bariatric surgery and in short bowel syndrome.

Main Results:

• Rivaroxaban and apixaban are effective in stable patients post-bariatric surgery (e.g., sleeve gastrectomy, Roux-en-Y gastric bypass).
• Dabigatran is less effective due to its reliance on gastric acidity for absorption.
• Warfarin is the recommended anticoagulant for severe malabsorption, such as very short bowel syndrome, due to its monitorable effect.
• DOACs are generally not recommended during the acute postoperative period (0-4 weeks).

Conclusions:

• Anticoagulant choice in malabsorptive conditions requires careful consideration of the specific drug and patient status.
• Drug-specific assays (anti-Xa, dilute thrombin time) are crucial for monitoring DOAC absorption when used.
• Individualized treatment strategies are necessary to ensure effective anticoagulation in patients with compromised GI absorption.